Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06858813 2025-11-10

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1 Recruiting

232 enrolled

Gastrointestinal

Liver Neoplasms

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

150 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

130 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

53 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05024214 2025-05-29

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

170 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Phase 2 Not yet recruiting

120 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06371157 2025-03-12

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Phase 3 Recruiting

469 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05195294 2025-03-10

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Phase 2 Not yet recruiting

55 enrolled

Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

NCT05301842 2025-01-15

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

263 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03418922 2024-06-20

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Phase 1 Completed

30 enrolled 28 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

59 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03006926 2023-12-13

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Phase 1 Completed

104 enrolled 41 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04297254 2023-11-15

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Phase 4 Completed

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Completed

412 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

NCT04741165 2021-02-05

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

72 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03663114 2021-01-22

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Completed

713 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02579616 2020-12-23

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase 2 Completed

29 enrolled 16 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT03433703 2019-12-06

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Phase 2 Terminated

8 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00946153 2019-02-01

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

66 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

Clinical Trials

MK-3475-06B

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

CheckMate 9DW

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

LEAP-002

MK-7902-017

TREMENDOUS-2

LEAP-012

MK-7902-014

LEAP-005

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

ALIVE

KEYVIBE-005

LIVIGNO-1

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

EMERALD-3

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)